MetaCap

Aldeyra Therapeutics (ALDX) vs Rafael (RFL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rafael (RFL) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 25.8% versus a loss of 83.1%. Over five years, RFL leads with a -84.2% price change compared with -89.1% for ALDX. Aldeyra Therapeutics is the larger company by market cap ($50.7 million vs $48.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALDX-83.06%RFL-25.83%
+220%+58%-103%
Nov 21, 20251 yearNov 20, 2026
ALDX-89.41%RFL-84.64%
+46%-27%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALDX versus RFL key metrics
MetricALDXRFL
Share price$0.84$0.9197
Market cap$50.70M$47.99M
1-day change+16.39%+2.19%
YTD return-83.78%-22.06%
1-year return-83.06%-25.83%
5-year return-89.06%-84.19%
EPS (TTM)$-0.31$-0.58
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$874.00K
Revenue growth (YoY)—-4.69%
Net income (latest FY)$-33.85M$-29.64M
Operating margin—-3822.54%
Net margin—-3390.73%
52-week high$5.93$3.96
52-week low$0.527$0.781
Distance from 52-week high-85.83%-76.78%
Analyst consensusstrong_buy—
Avg. price target upside+685.71%—
Average volume1.16M140.84K
Shares outstanding60.36M51.39M
Employees621
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RFL has outperformed ALDX by 57.2 percentage points over the past year.

About Aldeyra Therapeutics

ALDX stock →

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Rafael

RFL stock →

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

ALDX vs RFL FAQ

Which is bigger, Aldeyra Therapeutics or Rafael?

Aldeyra Therapeutics (ALDX) is larger, with a market capitalization of $50.70M compared with $47.99M for Rafael (RFL).

Which stock has performed better over the past year, ALDX or RFL?

RFL returned -25.83% over the past 12 months, compared with -83.06% for ALDX (price return, excluding dividends). Past performance does not predict future results.

Are Aldeyra Therapeutics and Rafael in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons